Some high blood pressure drugs may be associated with increased risk of vision-threatening disease

May 28, 2014

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

AMD – the deterioration of the eye's macula, which is responsible for the ability to see fine details clearly – affects an estimated 11 million people in the United States. In addition to increased age, the cause of AMD may be attributed to several risk factors, including hereditary risk and smoking. Some studies have also found an association between AMD and , but this has been inconsistent. To help clarify the relationship between AMD incidence and blood pressure lowering medications, including vasodilators, researchers from the University of Wisconsin School of Medicine and Public Health conducted a long-term population-based cohort study from 1988 to 2013 of nearly 5,000 residents of Beaver Dam, Wis., aged 43 to 86 years. The research is part of the National Eye Institute -funded Beaver Dam Eye Study, which has since 1987 collected information on the prevalence and incidence of AMD, and diabetic retinopathy.

The researchers found that, after adjusting for age, sex and other factors, using any vasodilator such as Apresoline and Loniten, which open (dilate) the blood vessels – was associated with a 72 percent greater risk of developing early-stage AMD. Among people who were not taking vasodilators, an estimated 8.2 percent developed signs of early AMD. In comparison, among those taking a vasodilator medication, 19.1 percent developed the disease.

The researchers also found that taking oral beta blockers such as Tenormin and Lopressor was associated with a 71 percent increase in the risk of neovascular AMD, a more advanced and vision-threatening form of the disease. Among those who were not taking oral beta blockers an estimated 0.5 percent developed signs of neovascular AMD. In comparison among those taking oral beta blockers, 1.2 percent developed neovascular AMD.

While the study provides risk estimates of associations between lowering medications and AMD at various stages, the researchers caution that their study was not able to discern effects of the medications themselves and the conditions for which participants were taking those medications.

"As significant as these results may be, it's important that they be replicated first, and if possible tested in a clinical trials setting before changing anyone's medication regimens," said Ronald Klein, M.D., MPH, lead researcher of the study. "Further research is needed to determine the cause of these increased risks."

Explore further: Regular aspirin use ten or more years ago associated with increased risk of type of age-related macular degeneration

Related Stories

Regular aspirin use ten or more years ago associated with increased risk of type of age-related macular degeneration

December 18, 2012
Among nearly 5,000 study participants, regular aspirin use reported ten years prior was associated with a small but statistically significant increase in the risk of neovascular age‑related macular degeneration, according ...

Genotyping IDs long-term risk of macular degeneration

November 13, 2012
(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing risk when early ...

Patients with AMD may not need monthly injections

May 6, 2014
Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary. The research is being presented at the 2014 Annual Meeting ...

Findings support link between hsCRP, macular degeneration

February 8, 2013
(HealthDay)—Pooled results from five cohorts confirm that high levels of high-sensitivity C-reactive protein (hsCRP) correlate with increased future risk of age-related macular degeneration (AMD), according to research ...

Researchers develop risk assessment model for advanced age-related macular degeneration

August 8, 2011
A new risk assessment model may help predict development of advanced age-related macular degeneration, according to a report published Online First by Archives of Ophthalmology, one of the JAMA/Archives journals.

Recommended for you

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

Nearly 60% of pinkeye patients receive antibiotic eye drops, but they're seldom necessary

June 28, 2017
A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

Magnetic implants used to treat 'dancing eyes'

June 26, 2017
A research team has successfully used magnets implanted behind a person's eyes to treat nystagmus, a condition characterised by involuntary eye movements.

Drug shows promise against vision-robbing disease in seniors

June 21, 2017
An experimental drug is showing promise against an untreatable eye disease that blinds older adults—and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.

Reproducing a retinal disease on a chip

June 15, 2017
Approximately 80% of all sensory input is received via the eyes, so suffering from chronic retinal diseases that lead to blindness causes a significant decrease in the quality of life (QOL). And because retinal diseases are ...

New gene therapy for vision loss proven safe in humans

May 16, 2017
In a small and preliminary clinical trial, Johns Hopkins researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.